OPEN SOURCE AUTOMATED INSULIN DELIVERY SYSTEMS: BENEFITS, LIMITATIONS AND CHALLENGES IN DIABETES CARE

被引:2
|
作者
Shishin, Konstantin S. [1 ,2 ]
Klimontov, Vadim V. [1 ]
机构
[1] Russian Acad Sci, Siberian Branch, Branch Inst Cytol & Genet, Res Inst Clin & Expt Lymphol, Novosibirsk, Russia
[2] Novosibirsk Natl Res State Univ, Novosibirsk, Russia
来源
DIABETES MELLITUS | 2023年 / 26卷 / 04期
关键词
diabetes; automated insulin delivery; insulin delivery system; artificial pancreas; closed loop; open source; continuous glucose monitoring; ARTIFICIAL PANCREAS;
D O I
10.14341/DM13022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Open source closed loop automated insulin delivery (CL-AID) systems are increasingly used in the treatment of diabetes. Assembled on a do-it-yourself (DIY) basis, these systems integrate insulin pumps, continuous glucose monitoring devices, and algorithms that control the rate of insulin delivery based on glucose levels. In this review, we consider the technological features of open source CL-AID systems (OpenAPS, AndroidAPS, Loop, etc.), advantages and barriers to their use in clinical practice. Advantages of open source CL-AID systems over commercially available ones included lower cost, a choice of devices, a wide range of user settings, as well as continuous improvement of algorithms. A growing body of evidence indicates that open source CL-AID systems, such as OpenAPS, AndroidAPS, and Loop, provide an excellent time in range with minimal risk of hypoglycaemia and increase treatment satisfaction in patients with type 1 diabetes. A wide range of settings makes open source systems an effective tool for managing diabetes in situations with rapidly changing insulin requirement. However, some technological, medical, legal and ethical issues associated with the use of non-commercial CL-AID systems still need to be addressed. Assembling the system requires skills in diabetes technology. The issue of cybersecurity is also relevant. Lack of official approvals, low awareness of medical professionals, and reimbursement issues are slowing down the introduction of the technology into clinical practice. The professional medical community at the international and national levels needs to determine its position regarding the use of open source CL-AID systems in the treatment of diabetes.
引用
收藏
页码:352 / 362
页数:11
相关论文
共 50 条
  • [31] Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes
    Senior, Peter
    Lam, Anna
    Farnsworth, Kate
    Perkins, Bruce
    Rabasa-Lhoret, Remi
    CURRENT DIABETES REPORTS, 2020, 20 (10)
  • [32] OPEN SOURCE: CONCEPTS, BENEFITS, AND CHALLENGES
    AlMarzouq, Mohammad
    Zheng, Li
    Rong, Guang
    Grover, Varun
    COMMUNICATIONS OF THE ASSOCIATION FOR INFORMATION SYSTEMS, 2005, 16 : 756 - 784
  • [33] User Experiences with Loop, an Open -Source Automated Insulin Delivery (AID) System
    Suttiratana, Sakinah
    Wong, Jessie J.
    Lanning, Monica S.
    Dunlap, Adrienne
    Hanes, Sarah
    Hood, Korey K.
    Lal, Rayhan
    Naranjo, Diana
    DIABETES, 2021, 70
  • [34] The First Regulatory Clearance of an Open-Source Automated Insulin Delivery Algorithm
    Braune, Katarina
    Hussain, Sufyan
    Lal, Rayhan
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023, : 1139 - 1141
  • [35] Psychosocial Effects of the Loop Open-Source Automated Insulin Delivery System
    Wong, Jessie J.
    Hood, Korey K.
    Hanes, Sarah J.
    Lal, Rayhan A.
    Naranjo, Diana
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023, 17 (06): : 1440 - 1447
  • [36] Impact of Hypoglycemia on Glucose Variability over Time for Individuals with Open-Source Automated Insulin Delivery Systems
    Shahid, Arsalan
    Lewis, Dana M.
    DIABETOLOGY, 2024, 5 (05): : 514 - 536
  • [37] Use of the Community-Derived Open-Source Automated Insulin Delivery Loop System in Type 2 Diabetes
    Bauza, Colleen
    Kanapka, Lauren G.
    Greene, Ellis
    Lal, Rayhan A.
    Arbiter, Brandon
    Beck, Roy W.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (07) : 494 - 497
  • [38] Switch of open-source automated insulin delivery system - AndroidAPS to commercially available AID systems in type 1 diabetes: the extension of the CODIAC study
    Do, D. Q.
    Haskova, A.
    Radovnicka, L.
    Horova, E.
    Konecna, J.
    Grunberger, G.
    Parkin, C.
    Prazny, M.
    Soupal, J.
    DIABETOLOGIA, 2024, 67 : S369 - S369
  • [39] Prevalence, Safety, and Metabolic Control Among Danish Children and Adolescents with Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems
    Fagerberg, Amanda R.
    Borch, Luise
    Kristensen, Kurt
    Hjelle, Jesper S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (05) : 287 - 297
  • [40] Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems
    Forlenza, Gregory P.
    Dai, Zheng
    Niu, Fang
    Shin, John J.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 : 7 - 16